BC Extra | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to severe agitation in patients with Alzheimer's dementia....
BC Extra | Mar 25, 2019
Clinical News

Avanir's AVP-786 meets in Phase III for Alzheimer's agitation

Avanir said one of two doses of AVP-786 met the primary endpoint of improving agitation symptoms in the Phase III 15-AVP-786-301 trial to treat agitation in patients with Alzheimer's dementia. AVP-786 comprises deuterium-modified dextromethorphan --...
BC Week In Review | Jul 21, 2017
Clinical News

Avanir begins Phase II trial of AVP-786 for neurobehavioral disinhibition from TBI

The Avanir Pharmaceuticals Inc. subsidiary of Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 (CTP-786) for up to 12 weeks in about 150 patients...
BC Week In Review | Dec 7, 2015
Clinical News

AVP-786: Phase III started

Otsuka began the double-blind, placebo-controlled, U.S. Phase III TRIAD-1 trial to evaluate 2 doses of oral AVP-786 twice daily for 12 weeks in about 380 patients. The start of the trial triggered a $2 million...
BC Week In Review | Sep 15, 2014
Clinical News

AVP-786: Phase II started

Avanir began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral AVP-786 for 10 weeks in about 200 patients with MDD who had an inadequate response to antidepressant treatment, including selective serotonin reuptake...
BC Week In Review | Jun 2, 2014
Clinical News

Dextromethorphan/quinidine: Completed Phase II enrollment

Avanir completed enrollment of 220 patients in the double-blind, placebo-controlled, U.S. Phase II AVR-131 trial to evaluate 20/10 and 30/10 mg oral dextromethorphan/quinidine twice daily for 10 weeks. Top-line data are expected in late September...
BC Extra | Feb 14, 2014
Financial News

Concert raises $84 million in IPO

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) raised $84 million in an IPO through the sale of a bumped-up number of shares at the high end of its proposed range. The company sold 6 million shares at $14,...
BC Extra | Feb 4, 2014
Financial News

Concert sets IPO terms

Concert Pharmaceuticals Inc. (Lexington, Mass.) amended its IPO and said it now plans to sell 5 million shares at $12-$14. At the $13 midpoint, the company -- which is seeking to list on NASDAQ --...
BC Extra | Jan 14, 2014
Financial News

Concert, Microlin Bio file for IPOs

Concert Pharmaceuticals Inc. (Lexington, Mass.) and Microlin Bio Inc. (New York City, N.Y.) both filed for IPOs on NASDAQ. Concert filed to raise up to $74.8 million in an IPO underwritten by UBS; Wells Fargo;...
BC Week In Review | Dec 16, 2013
Clinical News

Nuedexta dextromethorphan/quinidine: Phase II data

Top-line data from the double-blind, placebo-controlled, international Phase II PRIME trial in 209 MS patients with central neuropathic pain showed that twice-daily AVP-923 missed the primary endpoint of reducing Numeric PRS scores from baseline to...
Items per page:
1 - 10 of 12